"Antibodies, Monoclonal" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Antibodies produced by a single clone of cells.
| Descriptor ID |
D000911
|
| MeSH Number(s) |
D12.776.124.486.485.114.224 D12.776.124.790.651.114.224 D12.776.377.715.548.114.224
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Antibodies, Monoclonal".
Below are MeSH descriptors whose meaning is more specific than "Antibodies, Monoclonal".
This graph shows the total number of publications written about "Antibodies, Monoclonal" by people in this website by year, and whether "Antibodies, Monoclonal" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 4 | 11 | 15 |
| 1997 | 4 | 7 | 11 |
| 1998 | 6 | 16 | 22 |
| 1999 | 10 | 18 | 28 |
| 2000 | 7 | 12 | 19 |
| 2001 | 14 | 20 | 34 |
| 2002 | 11 | 14 | 25 |
| 2003 | 15 | 15 | 30 |
| 2004 | 23 | 16 | 39 |
| 2005 | 25 | 19 | 44 |
| 2006 | 26 | 15 | 41 |
| 2007 | 30 | 13 | 43 |
| 2008 | 21 | 21 | 42 |
| 2009 | 31 | 19 | 50 |
| 2010 | 37 | 22 | 59 |
| 2011 | 19 | 12 | 31 |
| 2012 | 17 | 11 | 28 |
| 2013 | 18 | 9 | 27 |
| 2014 | 17 | 12 | 29 |
| 2015 | 13 | 8 | 21 |
| 2016 | 15 | 7 | 22 |
| 2017 | 28 | 11 | 39 |
| 2018 | 23 | 15 | 38 |
| 2019 | 18 | 10 | 28 |
| 2020 | 15 | 17 | 32 |
| 2021 | 10 | 19 | 29 |
| 2022 | 4 | 19 | 23 |
| 2023 | 4 | 12 | 16 |
| 2024 | 16 | 6 | 22 |
| 2025 | 9 | 5 | 14 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antibodies, Monoclonal" by people in Profiles.
-
Comparing Outcomes With Subcutaneous Infliximab (CT-P13 SC) by Baseline Immunosuppressant Use: A Post Hoc Analysis of the LIBERTY-CD and LIBERTY-UC Studies. Inflamm Bowel Dis. 2025 Oct 01; 31(10):2714-2724.
-
Inhibitory activities of monoclonal antibodies against Staphylococcus aureus clumping factor A. mBio. 2025 Oct 08; 16(10):e0219725.
-
Genomic specificity of anti-mouse TCR mAbs determined by single-cell RNAseq. J Immunol. 2025 Sep 01; 214(9):2202-2210.
-
Durvalumab Plus Platinum-Etoposide in Extensive-Stage Small-Cell Lung Cancer: Outcomes in Age, Sex, and Platinum Subgroups From the Phase 3 CASPIAN Study. Clin Lung Cancer. 2025 Dec; 26(8):626-641.
-
Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for Crohn's disease and ulcerative colitis: 2-year results from open-label extensions of two randomized controlled trials (LIBERTY). J Crohns Colitis. 2025 Jun 04; 19(6).
-
Real-World Effectiveness and Safety of Evinacumab in Children and Adults With Homozygous Familial Hypercholesterolemia: A Multisite US Perspective-Brief Report. Arterioscler Thromb Vasc Biol. 2025 Jul; 45(7):1310-1315.
-
Adverse events self-reported by patients with extensive-stage small-cell lung cancer in the phase III CASPIAN study. Future Oncol. 2025 May; 21(12):1511-1523.
-
Mapping the extracellular molecular architecture of the pAg-signaling complex with a-Butyrophilin antibodies. Sci Rep. 2025 Apr 09; 15(1):12162.
-
Bortezomib, melphalan, and prednisone with or without daratumumab in transplant-ineligible patients with newly diagnosed multiple myeloma (ALCYONE): final analysis of an open-label, randomised, multicentre, phase 3 trial. Lancet Oncol. 2025 May; 26(5):596-608.
-
Corticosteroid-sparing effects of risankizumab efficacy and safety in patients with moderately to severely active ulcerative colitis. J Crohns Colitis. 2025 Apr 04; 19(4).